Key Takeaway: Travere Therapeutics has reported its financial results for the fourth quarter and full year of 2025. Notably, the company announced the full FDA approval of FILSPARI® (sparsentan), marking it as the first and only approved treatment for Focal Segmental Glomerulosclerosis (FSGS). This approval is a significant milestone for the company and its product portfolio.
Price reaction · baseline $28.54 (2026-02-19T16:00:00.000Z) · hit during market hours · clean, no other TVTX news in the window
day 0 close · peak
+2.7%
Market Sentiment Analysis
POSITIVE FACTORS
Travere Therapeutics received full FDA approval for FILSPARI®.
FILSPARI® is the first and only approved medicine for FSGS.
The financial results indicate strong performance for the year.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
4.7%
average across 9 past catalysts
Lead asset
sparsentan
Phase 3 · Immunoglobulin A Nephropathy
Full Press Release Details
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results View Full Press Release Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
Frequently Asked Questions
What financial results did Travere report for Q4 2025?
Travere Therapeutics reported its financial results for the fourth quarter and full year of 2025.
What is FILSPARI® approved for?
FILSPARI® is the first and only approved medicine for Focal Segmental Glomerulosclerosis (FSGS).
When was FILSPARI® approved by the FDA?
FILSPARI® received full FDA approval, marking a significant milestone for Travere Therapeutics.